Study Evaluating Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Filipino Children
Completed
- Conditions
- Pneumonia, Bacterial
- Registration Number
- NCT00724828
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
Evaluation of the carriage rate of Streptococcus pneumoniae in the nasopharynx of healthy children and the carriage rate and distribution of Streptococcus pneumoniae serotypes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Healthy children aged between 2 months and 5 years attending the well baby clinic in hospital.
- Informed consent obtained from parents or legal guardian.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Streptococcus pneumoniae serotype carriage rate based on a nasopharyngeal swab. 1 day
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the impact of pneumococcal serotype distribution on vaccine efficacy in Filipino children as studied in NCT00724828?
How does nasopharyngeal carriage of Streptococcus pneumoniae correlate with invasive disease risk in pediatric populations?
What molecular mechanisms underlie serotype-specific immune responses to pneumococcal colonization in children?
Are there specific biomarkers associated with high Streptococcus pneumoniae carriage rates in tropical climates like the Philippines?
How do observational studies like NCT00724828 contribute to understanding pneumococcal epidemiology for vaccine development?